Metabotropic Glutamate Receptor 5 (GPRC1E or MGLUR5 or GRM5) - Pipeline Review, H2 2017

Published: Aug, 2017 | Pages: 81 | Publisher: Global Markets Direct
Industry: Pharmaceuticals & Healthcare | Report Format: Electronic (PDF)

Metabotropic Glutamate Receptor 5 (GPRC1E or MGLUR5 or GRM5) - Pipeline Review, H2 2017

Summary

Metabotropic Glutamate Receptor 5 (GPRC1E or MGLUR5 or GRM5) - Metabotropic glutamate receptor 5 (mGluR5) is a G protein-coupled receptor. Ligand binding causes a conformation change that triggers signaling via guanine nucleotide-binding proteins (G proteins) and modulates the activity of down-stream effectors. Signaling activates a phosphatidylinositol calcium second messenger system and generates a calcium activated chloride current. mGluR5 plays an important role in the regulation of synaptic plasticity and the modulation of the neural network activity. 

Metabotropic Glutamate Receptor 5 (GPRC1E or MGLUR5 or GRM5) pipeline Target constitutes close to 26 molecules. Out of which approximately 19 molecules are developed by companies and remaining by the universities/institutes. The molecules developed by companies in Phase III, Phase II, Phase I, Preclinical and Discovery stages are 1, 2, 2, 12 and 2 respectively. Similarly, the universities portfolio in Preclinical stages comprises 7 molecules, respectively. Report covers products from therapy areas Central Nervous System, Genetic Disorders and Musculoskeletal Disorders which include indications Dyskinesia, Anxiety Disorders, Autism, Depression, Schizophrenia, Cognitive Impairment Associated With Schizophrenia (CIAS), Major Depressive Disorder, Alcohol Addiction, Alzheimer's Disease, Attention Deficit Hyperactivity Disorder (ADHD), Chronic Pain, Cognitive Disorders, Cognitive Impairment, DiGeorge Syndrome, Fragile X Syndrome, Generalized Anxiety Disorder (GAD), Mania, Neurology, Opium (Opioid) Addiction, Pain, Parkinson's Disease, Spasmodic Torticollis and Substance (Drug) Abuse. 

The latest report Metabotropic Glutamate Receptor 5 (GPRC1E or MGLUR5 or GRM5) - Pipeline Review, H2 2017, outlays comprehensive information on the Metabotropic Glutamate Receptor 5 (GPRC1E or MGLUR5 or GRM5) targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type. It also reviews key players involved in Metabotropic Glutamate Receptor 5 (GPRC1E or MGLUR5 or GRM5) targeted therapeutics development with respective active and dormant or discontinued projects.

The report is built using data and information sourced from proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope

- The report provides a snapshot of the global therapeutic landscape for Metabotropic Glutamate Receptor 5 (GPRC1E or MGLUR5 or GRM5)
- The report reviews Metabotropic Glutamate Receptor 5 (GPRC1E or MGLUR5 or GRM5) targeted therapeutics under development by companies and universities/research institutes based on information derived from company and industry-specific sources 
- The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages 
- The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities 
- The report reviews key players involved in Metabotropic Glutamate Receptor 5 (GPRC1E or MGLUR5 or GRM5) targeted therapeutics and enlists all their major and minor projects 
- The report assesses Metabotropic Glutamate Receptor 5 (GPRC1E or MGLUR5 or GRM5) targeted therapeutics based on mechanism of action (MoA), route of administration (RoA) and molecule type 
- The report summarizes all the dormant and discontinued pipeline projects 
- The report reviews latest news and deals related to Metabotropic Glutamate Receptor 5 (GPRC1E or MGLUR5 or GRM5) targeted therapeutics

Reasons To Buy

- Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage 
- Identify and understand the targeted therapy areas and indications for Metabotropic Glutamate Receptor 5 (GPRC1E or MGLUR5 or GRM5)
- Identify the use of drugs for target identification and drug repurposing
- Identify potential new clients or partners in the target demographic
- Develop strategic initiatives by understanding the focus areas of leading companies 
- Plan mergers and acquisitions effectively by identifying key players and it's most promising pipeline therapeutics
- Devise corrective measures for pipeline projects by understanding Metabotropic Glutamate Receptor 5 (GPRC1E or MGLUR5 or GRM5) development landscape 
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and Scope

 Table of Contents

Table of Contents 2
List of Tables 6
List of Figures 6
Introduction 7
Global Markets Direct Report Coverage 7
Metabotropic Glutamate Receptor 5 (GPRC1E or MGLUR5 or GRM5) - Overview 8
Metabotropic Glutamate Receptor 5 (GPRC1E or MGLUR5 or GRM5) - Therapeutics Development 9
Products under Development by Stage of Development 9
Products under Development by Therapy Area 10
Products under Development by Indication 11
Products under Development by Companies 14
Products under Development by Universities/Institutes 17
Metabotropic Glutamate Receptor 5 (GPRC1E or MGLUR5 or GRM5) - Therapeutics Assessment 19
Assessment by Mechanism of Action 19
Assessment by Route of Administration 21
Assessment by Molecule Type 22
Metabotropic Glutamate Receptor 5 (GPRC1E or MGLUR5 or GRM5) - Companies Involved in Therapeutics Development 23
Addex Therapeutics Ltd 23
Aevi Genomic Medicine Inc 23
Bristol-Myers Squibb Company 24
Eisai Co Ltd 24
Eli Lilly and Company 25
Heptares Therapeutics Ltd 25
Johnson & Johnson 26
Merz Pharma GmbH & Co KgaA 26
Novartis AG 27
Richter Gedeon Nyrt 27
Sumitomo Dainippon Pharma Co Ltd 28
Toray Industries Inc 28
Metabotropic Glutamate Receptor 5 (GPRC1E or MGLUR5 or GRM5) - Drug Profiles 29
alloswitch-1 - Drug Profile 29
Product Description 29
Mechanism Of Action 29
R&D Progress 29
BMS-952048 - Drug Profile 30
Product Description 30
Mechanism Of Action 30
R&D Progress 30
BMS-955829 - Drug Profile 31
Product Description 31
Mechanism Of Action 31
R&D Progress 31
dipraglurant ER - Drug Profile 32
Product Description 32
Mechanism Of Action 32
R&D Progress 32
dipraglurant IR - Drug Profile 33
Product Description 33
Mechanism Of Action 33
R&D Progress 33
Drug to Antagonize mGluR5 for Fragile X Syndrome and 16p11.2 Microdeletion Syndrome - Drug Profile 38
Product Description 38
Mechanism Of Action 38
R&D Progress 38
DSR-98776 - Drug Profile 39
Product Description 39
Mechanism Of Action 39
R&D Progress 39
fasoracetam - Drug Profile 40
Product Description 40
Mechanism Of Action 40
R&D Progress 40
GET-73 - Drug Profile 43
Product Description 43
Mechanism Of Action 43
R&D Progress 43
HTL-14242 - Drug Profile 44
Product Description 44
Mechanism Of Action 44
R&D Progress 44
JNJ-46778212 - Drug Profile 45
Product Description 45
Mechanism Of Action 45
R&D Progress 45
LSN-2814617 - Drug Profile 46
Product Description 46
Mechanism Of Action 46
R&D Progress 46
mavoglurant - Drug Profile 47
Product Description 47
Mechanism Of Action 47
R&D Progress 47
PAM-12 - Drug Profile 49
Product Description 49
Mechanism Of Action 49
R&D Progress 49
Small Molecule to Agonize Metabotropic Glutamate Receptor 5 for Cognitive Disorders - Drug Profile 50
Product Description 50
Mechanism Of Action 50
R&D Progress 50
Small Molecule to Antagonize mGlu5 for Persistent Pain - Drug Profile 51
Product Description 51
Mechanism Of Action 51
R&D Progress 51
Small Molecule to Antagonize mGluR5 for CNS Disorders - Drug Profile 52
Product Description 52
Mechanism Of Action 52
R&D Progress 52
Small Molecules to Agonize mGluR5 for Schizophrenia - Drug Profile 53
Product Description 53
Mechanism Of Action 53
R&D Progress 53
Small Molecules to Antagonize mGluR5 for Anxiety - Drug Profile 54
Product Description 54
Mechanism Of Action 54
R&D Progress 54
Small Molecules to Antagonize MGLUR5 for Anxiety Disorders - Drug Profile 55
Product Description 55
Mechanism Of Action 55
R&D Progress 55
Small Molecules to Antagonize mGLUR5 for Central Nervous System Disorders - Drug Profile 56
Product Description 56
Mechanism Of Action 56
R&D Progress 56
Small Molecules to Antagonize mGluR5 for Dyskinesia - Drug Profile 57
Product Description 57
Mechanism Of Action 57
R&D Progress 57
VU-0092273 - Drug Profile 58
Product Description 58
Mechanism Of Action 58
R&D Progress 58
VU-0431316 - Drug Profile 59
Product Description 59
Mechanism Of Action 59
R&D Progress 59
VU-0463841 - Drug Profile 60
Product Description 60
Mechanism Of Action 60
R&D Progress 60
VU-0467558 - Drug Profile 61
Product Description 61
Mechanism Of Action 61
R&D Progress 61
Metabotropic Glutamate Receptor 5 (GPRC1E or MGLUR5 or GRM5) - Dormant Products 62
Metabotropic Glutamate Receptor 5 (GPRC1E or MGLUR5 or GRM5) - Discontinued Products 65
Metabotropic Glutamate Receptor 5 (GPRC1E or MGLUR5 or GRM5) - Product Development Milestones 67
Featured News & Press Releases 67
May 10, 2017: Aevi Genomic Medicine Announces Plans to Initiate Phase 2 Clinical Trial to Confirm Genetic Responders to AEVI-001 67
Apr 20, 2017: Aevi Genomic Medicine Presents Updated Results from SAGA Trial of AEVI-001 at the 6th World Congress on ADHD 67
Apr 12, 2017: Aevi Genomic Medicine to Present Updated Results from SAGA Trial of AEVI-001 at the 6th World Congress on ADHD 69
Mar 20, 2017: Aevi Genomic Medicine Provides Top-line Results from the SAGA Trial of AEVI-001 69
Jan 31, 2017: Aevi Genomic Medicine Announces Enrollment of First Patient in Phase 1/2 Clinical Trial of AEVI-001 in 22q Deletion Syndrome 70
Jan 04, 2017: Aevi Genomic Medicine Announces Completion of Enrollment for Phase 2/3 SAGA Clinical Trial of AEVI-001 (NFC-1) in mGluR+ ADHD Adolescents 70
Oct 29, 2016: Medgenics Presents New Data Showing Prevalence of Genetic Mutations in Pediatric Populations with Attention Deficit Hyperactivity Disorder 71
Oct 17, 2016: Addex Therapeutics to Conduct Phase IIa Proof of Concept Study of Dipraglurant in Focal Cervical Dystonia 72
Jun 17, 2016: Medgenics Announces Enrollment of First Patient in Phase 2/3 Clinical Trial of NFC-1 in Adolescents With mGluR Mutation Positive ADHD 73
Jun 02, 2016: Addex Dipraglurant Positive Phase 2 Data in PD-LID Published in Leading Peer Reviewed Journal of the Movement Disorder Society 73
Apr 11, 2016: Addex Reports Positive Results of an mGlu5 Receptor Occupancy Study with Dipraglurant in Healthy Volunteers 74
Mar 15, 2016: Addex Reports Successful Completion of an mGlu5 Receptor Occupancy Study with Dipraglurant in Healthy Volunteers 76
Jan 11, 2016: Addex Dipraglurant Shows Highly Statistically Significant Anti-Dyskinetic Effects Following Additional Analysis of Data from the PD-LID Phase II Proof of Concept 77
Jan 04, 2016: Addex' Dipraglurant Receives Orphan Drug Designation from the FDA for Levodopa-Induced Dyskinesia Associated with Parkinson's Disease 77
Dec 17, 2015: Addex Reports Statistically Significant Positive Interim Data for Dipraglurant in Healthy Volunteer mGlu5 Receptor Occupancy Trial 78
Appendix 80
Methodology 80
Coverage 80
Secondary Research 80
Primary Research 80
Expert Panel Validation 80
Contact Us 80
Disclaimer 81

List of Tables

Number of Products under Development by Stage of Development, H2 2017 9
Number of Products under Development by Therapy Areas, H2 2017 10
Number of Products under Development by Indications, H2 2017 12
Number of Products under Development by Indications, H2 2017 (Contd..1), H2 2017 13
Number of Products under Development by Companies, H2 2017 14
Products under Development by Companies, H2 2017 15
Products under Development by Companies, H2 2017 (Contd..1), H2 2017 16
Number of Products under Investigation by Universities/Institutes, H2 2017 17
Products under Investigation by Universities/Institutes, H2 2017 18
Number of Products by Stage and Mechanism of Actions, H2 2017 20
Number of Products by Stage and Route of Administration, H2 2017 21
Number of Products by Stage and Molecule Type, H2 2017 22
Pipeline by Addex Therapeutics Ltd, H2 2017 23
Pipeline by Aevi Genomic Medicine Inc, H2 2017 23
Pipeline by Bristol-Myers Squibb Company, H2 2017 24
Pipeline by Eisai Co Ltd, H2 2017 24
Pipeline by Eli Lilly and Company, H2 2017 25
Pipeline by Heptares Therapeutics Ltd, H2 2017 25
Pipeline by Johnson & Johnson, H2 2017 26
Pipeline by Merz Pharma GmbH & Co KgaA, H2 2017 26
Pipeline by Novartis AG, H2 2017 27
Pipeline by Richter Gedeon Nyrt, H2 2017 27
Pipeline by Sumitomo Dainippon Pharma Co Ltd, H2 2017 28
Pipeline by Toray Industries Inc, H2 2017 28
Dormant Products, H2 2017 62
Dormant Products, H2 2017 (Contd..1), H2 2017 63
Dormant Products, H2 2017 (Contd..2), H2 2017 64
Discontinued Products, H2 2017 65
Discontinued Products, H2 2017 (Contd..1), H2 2017 66